Clinical Trials
5 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT01935973 2020-10-14
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01958112 2019-05-31
GSK1120212+GSK2141795 for Cervical Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01138085 2017-11-13
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
GlaxoSmithKline
Phase 1 Completed